70 results about "Injectable Solution" patented technology

Disclosed are storage stable aqueous infusible or injectable solutions containing an active substance of general formula (I)wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and in the specification, and an amount of a physiologically acceptable acid or mixture of acids sufficient to dissolve the active substance and act as a stabiliser, optionally together with other formulating excipients suitable for parenteral administration, and a process for preparing the infusible or injectable solutions according to the invention.

The present invention provides compositions and methods for tissue repair using a cytocompatible self-gelling cross-linked hydrogel. The composition comprises a biocompatible mixture of chitosan, bifunctional dialdehyde, and hydroxylated polymer, which can be used to immobilize or encapsulate viable cells, or bioactive substances. The method includes the process of mixing bioactive substances, live cells, and / or extracellular matrix components with a cross-linking solution comprising a bifunctional aldehyde-treated hydroxylated polymer such as hydroxyethyl cellulose. The cross-linking solution is then mixed homogenously with a neutral isotonic chitosan solution. The chitosan becomes cross-linked by the bifunctional aldehyde, while the cells are protected from potentially nocive effects of the aldehyde cross-linker by the hydroxylated polymer. The injectable solution retains cell viability and bioactivity, and immobilizes cells at the site of injection or delivery. Depending on the particular application, mixtures of chitosan and bifunctional dialdehyde may be employed. The injectable solution also liberates bioactive substances with controlled release kinetics from the site of injection.

A method for the substantially complete detection and measurement of all particles, within a predetermined size, range, contained in an injectable solution comprising the steps of: a) rotation of the container causes substantially all of the particles in the injectable solution in the container to be set in motion; b) uniformly illuminating the background around the container with light; and c) detecting at least one of light scatter, light reflection and light extinction caused by said particles, with detectors having a depth of focus of detection in a specified volume of the container. Wherein the detectors are positioned, relative to the container whereby the optical path and field of view allows the sensor sufficient focus to view substantially all of the bottom interior surface of the container and substantially all of the solution volume within the container. The method and apparatus produces a geometric representation of the particles in the detection region, whereby the size of detected particles can be is accurately adjusted to an actual size by either calculation or by calculated offset to allow accurate measurement of particle dimensions.

A pharmaceutical composition comprises, in powder form, (a) at least one water-soluble therapeutic agent selected from selective COX-2 inhibitory drugs and prodrugs and salts thereof, for example parecoxib sodium, in a therapeutically effective total amount constituting about 30% to about 90% by weight, (b) a parenterally acceptable buffering agent in an amount of about 5% to about 60% by weight, and optionally (c) other parenterally acceptable excipient ingredients in a total amount not greater than about 10% by weight, of the composition. The composition is reconstitutable in a parenterally acceptable solvent liquid to form an injectable solution. A lyophilization process is provided for preparation of such a composition.

A pharmaceutical composition of docetaxel comprising an effective amount of docetaxel, a polysorbate (TWEEN® compound) and a co-solvent, wherein the co-solvent is at least one member selected from the group consisting of glycerol and polyethylene glycol. The composition is an injectable solution or a freeze-dried powder for injection. The solubility of decetaxel is improved by adding a polysorbate and a co-solvent. Methods of preparation of the pharmaceutical composition are also disclosed.

Embodiments of this invention provide methods for thereapeutic use of cyclic G-2-Allyl Proline to treat disorders of dopaminergic neurons, including Parkinson's disease. Cyclic G-2Allyl P is neuroprotective and has utility as a therapeutic agent for treatment of diseases and other conditions characterised by degeneration and / or death of dopaminergic neurons and the adverse symptoms of such degeneration and / or death. Such symptoms include loss of cognition and motor function. Compounds are also useful for manufacture of medicaments including tablets, capsules and injectable solutions that are useful for treatment of such conditions.

In a first aspect, the present invention relates to a process for producing a stable, injectable solution with low content of noradrenaline, which includes dissolving noradrenaline and optionally an excipient in deoxygenated or degassed water, filtrating the resulting noradrenaline solution in a nitrogen current, distributing the solution in a nitrogen current, and sterilization, preferably hot. The invention further provides a stable, injectable solution with low content of noradrenaline, substantially free of anti-oxidizing and preservative agents, as well as uses thereof in the medical and pharmaceutical fields.

A drug injection device is disclosed. A drug injection device, according to the present invention, comprises: an injection unit which is provided with an ampoule accommodation portion for accommodating an ampoule that contains an injectable solution, and injects the injectable solution into a person being operated on; and an injection speed adjustment unit which is connected to the injection unit, applies pressure to the injectable solution, and adjusts the injection speed of the injectable solution, being injected into the body of the person being operated on, by selectively adjusting the speed of the pressure applied to the injectable solution, wherein the injection speed adjustment unit comprises: an injection unit attachment portion to which the ampoule accommodation portion is detachably attached; a pressurizing plunger which is connected to the ampoule accommodated in the ampoule accommodation portion and applies pressure to the injectable solution; and a pressurizing plunger up / down driving module which is provided on the same axis as the pressurizing plunger and drives the pressurizing plunger up or down.